Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2013-07-10FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin) from Allergan, Inc., resulting in changes to the product labeling. The acti…
-
FDA approval · 2013-07-03FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for OXYTROL (oxybutynin), updating the labeling for the product.
-
CLINICAL_TRIALS trial_result · 2013-07-03Clinical Trial Update: Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers [Phase 1]
Phase 1 pharmacokinetic interaction study assessing the effect of repeat doses of rifampin on mirabegron (YM178) in healthy volunteers has c…
-
CLINICAL_TRIALS trial_result · 2013-07-02Clinical Trial Update: A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) [Phase 2]
A Phase 2 clinical trial update for YM178 in symptomatic overactive bladder (DRAGON) reports that the study has completed.
-
CLINICAL_TRIALS trial_result · 2013-05-30Clinical Trial Update: Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder [Phase 4]
A Phase 4 clinical trial update assessing patient-reported goal attainment in the treatment of female overactive bladder. The study has comp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-05-29FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin), the transdermal patch from Allergan, Inc., signifying approval of updated …
-
FDA approval · 2013-05-24FDA Approved: TROSPIUM CHLORIDE ER — Original Application (Padagis US LLC)
FDA approved Padagis US LLC's original application for trospium chloride extended-release (trospium chloride ER), a generic version of the o…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: Overactive Bladder Innovative Therapy Trial (OrBIT) [Phase 4]
A Phase 4 trial update for the Overactive Bladder Innovative Therapy Trial (OrBIT) sponsored by Uroplasty, Inc. reports completion and poste…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms [Phase 4]
A Phase 4 extension study evaluating long-term use of percutaneous tibial nerve stimulation for overactive bladder symptoms completed with r…
-
CLINICAL_TRIALS trial_result · 2013-05-15Clinical Trial Update: Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder [Phase 4]
Phase 4 open-label extension trial evaluating the efficacy and safety of fesoterodine in elderly patients with overactive bladder. Results w…
-
CLINICAL_TRIALS trial_result · 2013-04-30Clinical Trial Update: Bladder Thermal Distention for Patients With Refractory Overactive Bladder [NA]
This clinical trial update concerns bladder thermal distention for patients with refractory overactive bladder; sponsor is Assaf-Harofeh Med…
-
FDA label_change · 2013-03-29FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approves a supplemental labeling application for Vesicare (solifenacin succinate) from Astellas Pharma US, updating the drug's labeling.
-
FDA approval · 2013-03-15FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2013-03-12Clinical Trial Update: A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. [Phase 4]
A Phase 4 trial evaluating fesoterodine in patients with overactive bladder who had insufficient response to tolterodine; results posted aft…
-
CLINICAL_TRIALS research · 2013-03-07Clinical Trial Update: Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy
Pfizer-sponsored non-interventional study investigated whether information provided to patients influences satisfaction with Toviaz (fesoter…
-
CLINICAL_TRIALS trial_result · 2013-03-05Clinical Trial Update: Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence [Phase 3]
Phase 3 trial results for botulinum toxin type A in idiopathic overactive bladder with urinary incontinence have been completed, with result…
-
CLINICAL_TRIALS trial_result · 2013-03-05Clinical Trial Update: Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence [Phase 3]
Phase 3 clinical trial update for botulinum toxin type A in idiopathic overactive bladder with urinary incontinence; the study has completed…
-
FDA approval · 2013-03-04FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA approves a supplemental application for MYRBETRIQ (mirabegron) by Astellas Pharma US, expanding the drug's label.
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia [Phase 4]
Phase 4 clinical trial evaluating solifenacin as add-on therapy for overactive bladder symptoms in men treated for benign prostatic hyperpla…
-
CLINICAL_TRIALS trial_result · 2013-01-31Clinical Trial Update: Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder [Phase 3]
A Phase 3 trial evaluating an electromagnetic stimulation device for urge urinary incontinence and overactive bladder was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-28Clinical Trial Update: The Best Parameter of Bladder Diary Correlates With the Volume at Strong Desire to Void of Filling Cystometry
This clinical trial update reports that the best parameter of the bladder diary correlates with the volume at the moment of strong desire to…
-
FDA approval · 2013-01-25FDA Approved: OXYTROL FOR WOMEN — Original Application (Allergan, Inc.)
The FDA approved OXYTROL FOR WOMEN (oxybutynin) under Allergan's original application. It is indicated for urinary symptoms associated with …
-
FDA approval · 2013-01-23FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency [Phase 2]
Phase 2 study of AOBO-001 for overactive bladder with urge urinary incontinence and frequency has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-21Clinical Trial Update: Trospium Chloride XR in Obese Female Patients With Overactive Bladder [Phase 4]
Phase 4 clinical trial update on trospium chloride XR in obese women with overactive bladder. The study status is completed with results pos…